Page last updated: 2024-09-04

nk 611 and Neutropenia

nk 611 has been researched along with Neutropenia in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cavalli, F; D'Incalci, M; De Fusco, M; de Jong, J; Hanauske, A; Kaeser-Fröhlich, A; Pagani, O; Sessa, C; Zucchetti, M1
Hanauske, AR; Kaeser-Fröhlich, A; Rassmann, I; Rastetter, J; Schilling, T; Schrödel, H; Zucchetti, M1

Trials

2 trial(s) available for nk 611 and Neutropenia

ArticleYear
Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative.
    Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:6

    Topics: Administration, Oral; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Podophyllotoxin; Thrombocytopenia

1996
Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 days.
    Investigational new drugs, 1996, Volume: 14, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Cell Count; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Podophyllotoxin

1996